Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

Bram Verstockt(Universitair Ziekenhuis Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Gert Van Assche(KU Leuven), An Outtier(KU Leuven), Isolde Aerden(KU Leuven), Nathalie Van den Berghe(KU Leuven), Ann Gils(KU Leuven), Griet Compernolle(KU Leuven), Séverine Vermeire(KU Leuven), Maja Noman(KU Leuven), Erwin Dreesen(KU Leuven)
Journal of Crohn s and Colitis
January 25, 2019
10.1093/ecco-jcc/jjz008
Cited by 123

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k